Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0004760
UniProt IDP14921
Primary gene name(s)ETS1
Synonym gene name(s)EWSR2
Protein nameProtein C-ets-1
Protein functionTranscription factor. Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts. May control the differentiation, survival and proliferation of lymphoid cells. May also regulate angiogenesis through regulation of expression of genes controlling endothelial cell migration and invasion. {ECO:0000269|PubMed:10698492, ECO:0000269|PubMed:11909962, ECO:0000269|PubMed:15247905, ECO:0000269|PubMed:15592518}.
Subcellular locationCytoplasm {ECO:0000269|PubMed:19377509}. Nucleus {ECO:0000269|PubMed:11909962, ECO:0000269|PubMed:19377509}. Note=Delocalizes from nucleus to cytoplasm when coexpressed with isoform Ets-1 p27. {ECO:0000269|PubMed:19377509}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P14921
Gene Ontology
(Biological Process)
Complete annatation
angiogenesis involved in wound healing [GO:0060055];
cell motility [GO:0048870];
cellular response to hydrogen peroxide [GO:0070301];
estrous cycle [GO:0044849];
female pregnancy [GO:0007565];
hypothalamus development [GO:0021854];
immune response [GO:0006955];
negative regulation of cell cycle [GO:0045786];
negative regulation of cell proliferation [GO:0008285];
negative regulation of inflammatory response [GO:0050728];
pituitary gland development [GO:0021983];
PML body organization [GO:0030578];
positive regulation of angiogenesis [GO:0045766];
positive regulation of cell proliferation [GO:0008284];
positive regulation of cellular component movement [GO:0051272];
positive regulation of endothelial cell migration [GO:0010595];
positive regulation of erythrocyte differentiation [GO:0045648];
positive regulation of inflammatory response [GO:0050729];
positive regulation of leukocyte adhesion to vascular endothelial cell [GO:1904996];
positive regulation of transcription, DNA-templated [GO:0045893];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
pri-miRNA transcription from RNA polymerase II promoter [GO:0061614];
regulation of angiogenesis [GO:0045765];
regulation of apoptotic process [GO:0042981];
regulation of extracellular matrix disassembly [GO:0010715];
response to antibiotic [GO:0046677];
response to estradiol [GO:0032355];
response to hypoxia [GO:0001666];
response to interleukin-1 [GO:0070555];
response to laminar fluid shear stress [GO:0034616];
response to mechanical stimulus [GO:0009612];
transcription from RNA polymerase II promoter [GO:0006366]
Gene Ontology
(Molecular Function)
Complete annatation
DNA binding [GO:0003677];
identical protein binding [GO:0042802];
RNA polymerase II transcription factor activity, sequence-specific DNA binding [GO:0000981];
sequence-specific DNA binding [GO:0043565];
transcription factor activity, sequence-specific DNA binding [GO:0003700];
transcription factor binding [GO:0008134]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
transcription factor complex [GO:0005667]
Protein-protein interaction108414
Phylogenetic treeP14921
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.0350079247958340.9146564888967160.944420264482517
AZA vs. DISU-0.4188981988754790.09728310557516010.635137056389055
AZA vs. IL70.07542406803182430.6935925393082650.999311006273513
AZA vs. SAHA-0.1686965605111640.4882721102205130.813492456184085
DISU vs. CD3-0.3956500744706080.2746382548348290.40351383165006
DISU vs. IL70.4849780261254390.05417508788971470.30709031023286
DISU vs. SAHA0.2515627172737930.3876885884484510.753702163765953
DMSO vs. AZA0.004279252683290690.979506218070281
DMSO vs. CD30.02944868316938510.9264841726864340.94910132337285
DMSO vs. DISU0.4218419126323220.08353205616762470.535720777090477
DMSO vs. IL70.07809793738662470.6625756294564650.930888829953308
DMSO vs. SAHA-0.1798540809240330.4442832782744640.776743605602472
HIV vs. Mock in Activation0.3171057857073040.6105097008344410.999983755607037
HIV vs. Mock in Latency0.2354364054693470.1516246842777650.999834320637052
IL7 vs. CD30.1174822998619170.7141766783190460.806713509615031
SAHA vs. CD3-0.1577394443741250.6550466391825490.743161402703066
SAHA vs. IL7-0.247143625887660.3089300360729550.557902403709562
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
FAIL 0 1
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.788 0.773 0.498 0.584 0.853
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1GVJ X-ray 1.5Å A/B=297-441.
2NNY X-ray 2.5Å A/B=280-441.
2STT NMR - A=320-415.
2STW NMR - A=320-415.
3MFK X-ray 3.0Å A/B=280-441.
3RI4 X-ray 3.0Å A/D=280-441.
3WTS X-ray 2.3Å C/H=276-441.
3WTT X-ray 2.3Å C/H=276-441.
3WTU X-ray 2.7Å C/H=276-441.
3WTV X-ray 2.7Å C/H=276-441.
3WTW X-ray 2.9Å C/H=276-441.
3WTX X-ray 2.8Å C/H=276-441.
3WTY X-ray 2.7Å C/H=276-441.
3WTZ X-ray 2.6Å A/B=276-441.
3WU0 X-ray 2.6Å A/B=276-441.
3WU1 X-ray 2.4Å B=333-441.
4L0Y X-ray 2.5Å B=296-441.
4L0Z X-ray 2.7Å B=296-441.
4L18 X-ray 2.3Å B/F=296-441.
4LG0 X-ray 2.1Å B=331-440.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat associates with 22073215
Tat interacts with 17376198
22073215

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04014 Ras signaling pathway - Homo sapiens (human)
hsa04320 Dorso-ventral axis formation - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05211 Renal cell carcinoma - Homo sapiens (human)
Menu